Eximias


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Company (Alive / Active)

Phone:

Fax:

Berwyn, 19312
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Eximias $0M Dec 4, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Eximias Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Horizon Therapeutics

Skokie, Illinois, United States
Alive / ActiveHorizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a portfolio of therapies through combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combinati...Show allLogin to see details

Quintessence Biosciences

Madison, Wisconsin, United States
Alive / ActiveQuintessence Biosciences is a biopharmaceutical company focused on development of-based therapeutics as anti-cancer agents. The Company's products are based on the EVade Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)